Two million Covid-19 vaccine doses from India reach Dhaka airport

India is shipping vaccines free of cost to many of its neighbours

Topics
Coronavirus Vaccine | Coronavirus | Coronavirus Tests

IANS  |  Dhaka 

Consignment of Covid-19 vaccine reaches Bhutan from India
A consignment of Covid-19 vaccine | Representational image

Two million doses of the Oxford-AstraZeneca Covid-19 vaccine made by the Serum Institute of India arrived in Dhaka on Thursday as a gift from New Delhi.

The Air India charter flight 1232 from Mumbai carrying the consignment landed at Shahjalal International Airport in Dhaka at 11.20 a.m. on Thursday.

In a tweet, Indian Minister of External Affars S Jaishankar said: "Touchdown in Dhaka.

#VaccineMaitri reaffirms the highest priority accorded by India to relations with Bangladesh."

The vaccines which came as a gift will be handed over at a formal ceremony at State Guesthouse Padma on Thursday afternoon.

Bangladesh Foreign Minister AK Abdul Momen, Health Minister Zahid Maleque, State Minister for Foreign Affairs Md Shahriar Alam, High Commissioner of India to Bangladesh Vikram Kumar Doraiswami and other high government officials will be in attendance.

The Serum Institute of India has produced the Covid-19 vaccine developed by the University of Oxford and drug maker AstraZeneca.

On January 8, Bangladesh approved the procurement of 30 million doses of Covishield vaccine from India.

"So, there would be plenty of vaccines in the country, we're quite assured now. We can start the vaccination programme ahead of the schedule," Momen told IANS.

Momen added that more countries including Russia and China, were interested in providing vaccines.

An agreement was signed in November 2020 between the Bangladesh government and the Serum Institute of India through which Beximco will avail 30 million doses of the Covid-19 vaccine.

In the initial six months of the first phase, Beximco will procure five million vaccine doses per month.

--IANS

sumi/ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Thu, January 21 2021. 13:55 IST
RECOMMENDED FOR YOU